TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Healthscope Receives Takeover Bid Australia's Healthscope received a takeover offer from a private-equity consortium, valuing the private hospital and pathology operator at $1.74 billion. online.wsj.com |
A Delay in Protalix's Uplyso FDA Review Is Not a Disaster EP Vantage submits:Unlike the World Cup, in the race to get a product on the market in an orphan indication there are no silver or bronze medals, only a standard 10-month regulatory review period. This is what Protalix (PLX) has learned as the FDA handed it a standard review, with a February 25, 2011, PDUFA date, for the Gaucher’s disease drug Uplyso.With the continued uncertainty over the supply of Genzyme’s (GENZ) Cerezyme (Genzyme moves on but faces uncertain future, May 25, 2010), many observers had been expecting an expedited review for Uplyso. However, the entrance of Shire’s (SHPGY) Vpriv into the marketplace may be filling the gap. With Genzyme having told analysts and investors that Cerezyme production will slowly increase from current 50% levels in late summer, perhaps the FDA believed market demand was being met and another expedited review was unnecessary.Complete Story » seekingalpha.com |
Where Does the WuXi Deal Breakup Leave Charles River? Derek Lowe submits: So when Charles River Laboratories (CRL) announced that it was buying WuXi (WX), its stock dropped pretty sharply. But unlike many other takeovers, it never recovered, and a lot of the company's shareholders seem to have continued to be unhappy about the deal. Unhappy enough so that on Friday the whole thing was called off. As that article makes clear, this is being seen as a particular victory for Jana, a hedge fund that's the largest single Charles River shareholder.Complete Story » seekingalpha.com |
Private Biotechs Take Different Avenues to Rake in Cash The Burrill Report submits: By Marie DaghlianReata Pharmaceuticals is filling its coffers ahead of late stage trials with a lucrative deal for its mid-stage treatment for chronic kidney disease. The private Irving, Texas-based biopharma is granting Abbott Laboratories (ABT) exclusive rights to develop and commercialize bardoxolone outside the United States, excluding certain Asian markets. In return, Reata will receive $450 million in upfront and near-term payments, and a minority equity investment in the company. Complete Story » seekingalpha.com |
BioClinica Launches Clinical Technology Breakthrough - Trident IWR [Business Wire] - BioClinica®, Inc., , a leading global provider of clinical trial management services, today announced the launch of its new IVR/IWR platform, Trident IWR, at the 2010 Society for Clinical Data Management Annual Conference . us.rd.yahoo.com |